News

While life with ALS brings continued disease progression, columnist Kristin Neva is encouraged by signs of renewal outdoors.
The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...
Columnist Dagmar Munn shares the strategy that helps her get unstuck when she's not feeling motivated. Time is precious with ALS, she says.
A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...
AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...
The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).
Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...
Columnist Dagmar Munn explains how the use of a shoehorn not only helps her put on shoes, but also allows for some gentle stretching.
RAG-17 therapy slowed functional decline and stabilized or improved breathing in people with ALS who carry mutations in the SOD1 gene.